XML 128 R82.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Operating Segments [Abstract] |
Summary of Net Sales by Segment and Geographical Area | The table below sets forth Sanofi’s net sales for the years ended December 31, 2023, 2022 and 2021:
(€ million) | Europe | United States | Other countries | 2023 | Europe | United States | Other countries | 2022(a) | Europe | United States | Other countries | 2021(b)
Biopharma | 8,835 |  | 17,265 |  | 11,790 |  | 37,890 |  | 8,498 |  | 16,985 |  | 12,329 |  | 37,812 |  | 8,426 |  | 13,246 |  | 11,621 |  | 33,293 |
Specialty Care | 3,206 |  | 11,917 |  | 2,917 |  | 18,040 |  | 3,016 |  | 10,848 |  | 2,593 |  | 16,457 |  | 2,764 |  | 7,847 |  | 2,141 |  | 12,752 |
of which | DUPIXENT | 1,224 |  | 8,145 |  | 1,346 |  | 10,715 |  | 940 |  | 6,346 |  | 1,007 |  | 8,293 |  | 649 |  | 3,971 |  | 629 |  | 5,249 |
| AUBAGIO | 437 |  | 460 |  | 58 |  | 955 |  | 511 |  | 1,420 |  | 100 |  | 2,031 |  | 512 |  | 1,312 |  | 131 |  | 1,955 |
| CEREZYME | 229 |  | 189 |  | 269 |  | 687 |  | 239 |  | 194 |  | 274 |  | 707 |  | 244 |  | 173 |  | 266 |  | 683 |
| FABRAZYME | 241 |  | 503 |  | 247 |  | 991 |  | 228 |  | 471 |  | 239 |  | 938 |  | 223 |  | 395 |  | 226 |  | 844 |
| MYOZYME/ LUMIZYME | 341 |  | 254 |  | 188 |  | 783 |  | 408 |  | 318 |  | 232 |  | 958 |  | 410 |  | 373 |  | 220 |  | 1,003 |
| JEVTANA | 12 |  | 230 |  | 78 |  | 320 |  | 33 |  | 275 |  | 83 |  | 391 |  | 112 |  | 253 |  | 90 |  | 455 |
| ALPROLIX | — |  | 440 |  | 100 |  | 540 |  | — |  | 406 |  | 98 |  | 504 |  | — |  | 332 |  | 82 |  | 414 |
| ELOCTATE | — |  | 341 |  | 130 |  | 471 |  | — |  | 450 |  | 130 |  | 580 |  | — |  | 429 |  | 134 |  | 563 |
General Medicines | 3,932 |  | 2,084 |  | 6,360 |  | 12,376 |  | 4,141 |  | 2,846 |  | 7,140 |  | 14,127 |  | 4,437 |  | 2,637 |  | 7,144 |  | 14,218 |
Core Assets | 1,988 |  | 1,485 |  | 2,797 |  | 6,270 |  | 1,917 |  | 1,653 |  | 2,819 |  | 6,389 |  | 1,868 |  | 1,315 |  | 2,585 |  | 5,768 |
of which | LOVENOX | 622 |  | 7 |  | 496 |  | 1,125 |  | 658 |  | 17 |  | 635 |  | 1,310 |  | 703 |  | 29 |  | 754 |  | 1,486 |
| TOUJEO | 441 |  | 213 |  | 469 |  | 1,123 |  | 421 |  | 283 |  | 413 |  | 1,117 |  | 394 |  | 259 |  | 316 |  | 969 |
| PLAVIX | 96 |  | 8 |  | 844 |  | 948 |  | 101 |  | 9 |  | 873 |  | 983 |  | 115 |  | 9 |  | 805 |  | 929 |
Non-Core Assets | 1,396 |  | 592 |  | 3,536 |  | 5,524 |  | 1,637 |  | 1,176 |  | 4,305 |  | 7,118 |  | 1,846 |  | 1,281 |  | 4,515 |  | 7,642 |
of which | LANTUS | 357 |  | 281 |  | 782 |  | 1,420 |  | 426 |  | 757 |  | 1,076 |  | 2,259 |  | 474 |  | 861 |  | 1,159 |  | 2,494 |
| Other non-core assets | 961 |  | 302 |  | 2,424 |  | 3,687 |  | 1,129 |  | 412 |  | 2,840 |  | 4,381 |  | 1,285 |  | 410 |  | 3,034 |  | 4,729 |
Industrial sales | 548 |  | 7 |  | 27 |  | 582 |  | 587 |  | 17 |  | 16 |  | 620 |  | 723 |  | 41 |  | 44 |  | 808 |
Vaccines | 1,697 |  | 3,264 |  | 2,513 |  | 7,474 |  | 1,341 |  | 3,291 |  | 2,596 |  | 7,228 |  | 1,225 |  | 2,762 |  | 2,336 |  | 6,323 |
of which | Polio/Pertussis/ Hib Vaccines | 297 |  | 398 |  | 1,470 |  | 2,165 |  | 325 |  | 456 |  | 1,504 |  | 2,285 |  | 306 |  | 470 |  | 1,383 |  | 2,159 |
| Influenza Vaccines | 694 |  | 1,406 |  | 569 |  | 2,669 |  | 681 |  | 1,737 |  | 559 |  | 2,977 |  | 729 |  | 1,366 |  | 533 |  | 2,628 |
Consumer Healthcare | 1,557 |  | 1,247 |  | 2,376 |  | 5,180 |  | 1,501 |  | 1,290 |  | 2,394 |  | 5,185 |  | 1,333 |  | 1,139 |  | 1,996 |  | 4,468 |
of which | Allergy | 70 |  | 412 |  | 287 |  | 769 |  | 55 |  | 439 |  | 276 |  | 770 |  | 49 |  | 371 |  | 192 |  | 612 |
| Pain Care | 502 |  | 180 |  | 424 |  | 1,106 |  | 555 |  | 212 |  | 424 |  | 1,140 |  | 515 |  | 196 |  | 382 |  | 1,093 |
| Digestive Wellness | 520 |  | 138 |  | 844 |  | 1,502 |  | 432 |  | 144 |  | 822 |  | 1,449 |  | 389 |  | 124 |  | 618 |  | 1,131 |
Total net sales | 10,392 |  | 18,512 |  | 14,166 |  | 43,070 |  | 9,999 |  | 18,275 |  | 14,723 |  | 42,997 |  | 9,759 |  | 14,385 |  | 13,617 |  | 37,761 |
(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January 1, 2023. (b) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.
Schedule of Segment Results | The table below shows Sanofi’s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:
| 2023
(€ million) | Biopharma | Consumer Healthcare | Other(a) | Total Sanofi
Net sales | 37,890 |  | 5,180 |  | — |  | 43,070 |
Other revenues | 3,322 |  | 52 |  | — |  | 3,374 |
Cost of sales | (12,282) |  | (1,933) |  | (1) |  | (14,216) |
Research and development expenses | (6,509) |  | (219) |  | — |  | (6,728) |
Selling and general expenses | (8,868) |  | (1,828) |  | 4 |  | (10,692) |
Other operating income and expenses | (2,387) |  | 181 |  | (18) |  | (2,224) |
Share of profit/(loss) from investments accounted for using the equity method | 101 |  | 21 |  | — |  | 122 |
Net income attributable to non-controlling interests | (20) |  | (16) |  | — |  | (36) |
Business operating income | 11,247 |  | 1,438 |  | (15) |  | 12,670 |
(a) This caption reconciles segment financial information to total consolidated financial information.
| 2022(a)
(€ million) | Biopharma | Consumer Healthcare | Other(b) | Total Sanofi
Net sales | 37,812 |  | 5,185 |  | — |  | 42,997 |
Other revenues | 2,330 |  | 62 |  | — |  | 2,392 |
Cost of sales | (11,793) |  | (1,903) |  | 4 |  | (13,692) |
Research and development expenses | (6,503) |  | (205) |  | 2 |  | (6,706) |
Selling and general expenses | (8,736) |  | (1,761) |  | 5 |  | (10,492) |
Other operating income and expenses | (1,679) |  | 148 |  | 17 |  | (1,514) |
Share of profit/(loss) from investments accounted for using the equity method | 76 |  | 12 |  | — |  | 88 |
Net income attributable to non-controlling interests | (17) |  | (16) |  | — |  | (33) |
Business operating income | 11,490 |  | 1,522 |  | 28 |  | 13,040 |
(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January 1, 2023. (b) This caption reconciles segment financial information to total consolidated financial information.
| 2021(a)
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Other(b) | Total Sanofi
Net sales | 26,970 |  | 6,323 |  | 4,468 |  | — |  | 37,761 |
Other revenues | 264 |  | 1,095 |  | 55 |  | — |  | 1,414 |
Cost of sales | (6,965) |  | (3,430) |  | (1,606) |  | (250) |  | (12,251) |
Research and development expenses | (4,330) |  | (712) |  | (153) |  | (497) |  | (5,692) |
Selling and general expenses | (5,326) |  | (805) |  | (1,388) |  | (2,036) |  | (9,555) |
Other operating income and expenses | (1,172) |  | 128 |  | 111 |  | (13) |  | (946) |
Share of profit/(loss) from investments accounted for using the equity method | 17 |  | 11 |  | 11 |  | — |  | 39 |
Net income attributable to non-controlling interests | (49) |  | (1) |  | (5) |  | (1) |  | (56) |
Business operating income | 9,409 |  | 2,609 |  | 1,493 |  | (2,797) |  | 10,714 |
(a) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure. (b) This caption reconciles segment financial information to total consolidated financial information.
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method | The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segments and Income before tax and investments accounted for using the equity method:
(€ million) | 2023 | 2022 | 2021 |
Business operating income | 12,670 |  | 13,040 |  | 10,714 |  |
Share of profit/(loss) from investments accounted for using the equity method(a) | (122) |  | (88) |  | (39) |  |
Net income attributable to non-controlling interests(b) | 36 |  | 33 |  | 56 |  |
Amortization and impairment of intangible assets(c) | (3,068) |  | (1,599) |  | (1,772) |  |
Fair value remeasurement of contingent consideration | (93) |  | 27 |  | (4) |  |
Expenses arising from the impact of acquisitions on inventories(d) | (20) |  | (3) |  | (4) |  |
Restructuring costs and similar items | (1,490) |  | (1,336) |  | (820) |  |
Other gains and losses, and litigation | (38) |  | (370) |  | (5) |  |
Income from out-licensing(e) | — |  | 952 |  | — |  |
Operating income | 7,875 |  | 10,656 |  | 8,126 |  |
Financial expenses | (1,313) |  | (440) |  | (368) |  |
Financial income | 591 |  | 206 |  | 40 |  |
Income before tax and investments accounted for using the equity method | 7,153 |  | 10,422 |  | 7,798 |  |
(a) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. For 2022, this line includes a reversal of €2,154 million on ELOCTATE franchise products following FDA approval of ALTUVIIIO dated February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non-alpha interleukin-2). (d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (e) For 2022, this line includes an upfront payment of $900 million and a regulatory milestone payment of $100 million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note C.1.).
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment | Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.
| 2023
(€ million) | Biopharma | Consumer Healthcare | Total
Investments accounted for using the equity method | 234 |  | 28 |  | 262 |
Acquisitions of property, plant and equipment | 1,619 |  | 100 |  | 1,719 |
Acquisitions of other intangible assets | 1,287 |  | 18 |  | 1,305 |
| 2022(a)
(€ million) | Biopharma | Consumer Healthcare | Total
Investments accounted for using the equity method | 248 |  | 37 |  | 285 |
Acquisitions of property, plant and equipment | 1,529 |  | 77 |  | 1,606 |
Acquisitions of other intangible assets | 574 |  | 21 |  | 595 |
(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January 1, 2023.
(€ million) | 2021(a)
Pharmaceuticals | Vaccines | Consumer Healthcare | Total
Investments accounted for using the equity method | 159 |  | 91 |  | — |  | 250 |
Acquisitions of property, plant and equipment | 1,024 |  | 382 |  | 73 |  | 1,479 |
Acquisitions of other intangible assets | 451 |  | 108 |  | 6 |  | 565 |
(a) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.
Summary of Geographical Information on Net Sales and Non-Current Assets | The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.
| 2023
(€ million) | Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 43,070 |  | 10,392 |  | 2,379 |  | 19,216 |  | 18,512 |  | 13,462 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 10,160 |  | 5,659 |  | 3,085 |  | 3,316 |  | 2,322 |  | 1,185 |
•goodwill | 49,404 |  | — |  | — |  | — |  | — |  | — |
▪other intangible assets | 24,319 |  | 5,566 |  | — |  | 17,852 |  | — |  | 901 |
| 2022
Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 42,997 |  | 9,999 |  | 2,296 |  | 18,984 |  | 18,275 |  | 14,014 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 9,869 |  | 5,365 |  | 2,875 |  | 3,284 |  | 2,457 |  | 1,220 |
•goodwill | 49,892 |  | — |  | — |  | — |  | — |  | — |
•other intangible assets | 21,640 |  | 6,257 |  | — |  | 14,178 |  | — |  | 1,205 |
(€ million) | 2021
Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 37,761 |  | 9,759 |  | 2,256 |  | 15,075 |  | 14,385 |  | 12,927 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 10,028 |  | 5,959 |  | 3,253 |  | 2,998 |  | 2,234 |  | 1,071 |
•goodwill | 48,056 |  | — |  | — |  | — |  | — |  | — |
•other intangible assets | 21,407 |  | 7,059 |  | — |  | 13,187 |  | — |  | 1,161 |

X
- Definition The disclosure of geographical information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 33 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment. + References No definition available. + Details
Name: | sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of net sales by segment and geographical area. + References No definition available. + Details
Name: | sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments reconciling items. + References No definition available. + Details
Name: | sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Operating Segments [Abstract] + References No definition available. + Details
Name: | sny_OperatingSegmentsAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration